Federica O’Brien

Freddi O’Brien has been serving as a financial and business operations consultant to ImmunoGenesis since September 2020 and became CFO in November 2021. Ms. O’Brien is President of CFO’Brien Consulting, LLC, for which she provides executive-level strategic and financial consulting services. She has held the roles of Chief Financial Officer, Chief Operating Officer, Controller, and Director of Financial Reporting and has been integral in the growth and financing of both private and public companies ranging from preclinical through commercial stage. She partners with Genova Group, LLC, to provide technical accounting and with Sonia Deggs, who provides the controllership and financial reporting of ImmunoGenesis.

Ms. O’Brien currently serves on the Board of Directors of TELA Bio, Inc., a commercial-stage medical technology company, where she chairs the Audit Committee. She also serves on the Board of Directors of MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and is a member of the Audit Committee.

Her corporate experience includes senior leadership roles at Complexa Inc., Cerecor Inc., Cervilenz Inc., Cardiokine Inc., Barrier Therapeutics Inc., and Infonautics Inc. Before specializing in life sciences and technology, Ms. O’Brien spent over a decade in professional service accounting firms, including PricewaterhouseCoopers, where she was focused on high-growth companies in multiple industries, including pharma. She received a BA in accounting from Rutgers University and is a Certified Public Accountant (inactive).